301
Participants
Start Date
July 31, 2015
Primary Completion Date
August 31, 2020
Study Completion Date
August 31, 2020
VX15/2503
VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
Placebo
Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
Columbia University, New York
Columbia University, New York
University of Rochester, Rochester
Georgetown University, Washington D.C.
Johns Hopkins University, Baltimore
Virginia Commonwealth University, Richmond
Wake Forest University, Winston-Salem
Duke University Health Center, Durham
Emory University School of Medicine, Atlanta
University of Florida Gainesville, Gainesville
University of Alabama at Birmingham, Birmingham
Vanderbilt University, Nashville
University of Louisville, Louisville
Ohio State University, Columbus
University of Toledo, Toledo
University of Cincinnati, Cincinnati
Indiana University School of Medicine, Indianapolis
University of Michigan, Ann Arbor
University of Iowa, Iowa City
Washington University, St Louis
University of Texas Houston Medical School, Houston
University of Colorado - Denver, Aurora
University of California, San Diego, La Jolla
University of California San Francisco, San Francisco
University of Washington and VA Puget Sound Health Care System, Seattle
University of Washington, Seattle
Beth Israel Deaconess Medical Center, Boston
Massachusetts General Hospital, Charlestown
University of Vermont, Burlington
University of Alberta, Edmonton
University of British Columbia, Vancouver
Centre hospitalier de l'Université de Montréal (CHUM), Montreal
Huntington Study Group
NETWORK
Vaccinex Inc.
INDUSTRY